This report focused on patients whose genotypes involved non-PTPN11 genes, irrespective of whether an NS or other non-Noonan RASopathy had been suspected, with emphasis on data relating to the suitability of rhGH treatment. This evidence concerns the gene PTPN11 and RASopathy.